2023
Disparities in immune and targeted therapy utilization for older US patients with metastatic renal cell carcinoma
Chow R, Long J, Hassan S, Wheeler S, Spees L, Leapman M, Hurwitz M, McManus H, Gross C, Dinan M. Disparities in immune and targeted therapy utilization for older US patients with metastatic renal cell carcinoma. JNCI Cancer Spectrum 2023, 7: pkad036. PMID: 37202354, PMCID: PMC10276895, DOI: 10.1093/jncics/pkad036.Peer-Reviewed Original ResearchMeSH KeywordsAgedCarcinoma, Renal CellEthnicityFemaleHumansKidney NeoplasmsMaleMedicareUnited StatesWhiteConceptsOral anticancer agentsTherapy utilizationMedicare beneficiariesNon-Hispanic white raceMetastatic renal cell carcinomaNon-Hispanic black raceOlder US patientsUS Medicare beneficiariesRenal cell carcinomaLogistic regression modelsTherapy receiptMultivariable adjustmentSystemic therapyMale sexUS patientsCell carcinomaStudy criteriaBlack raceFemale sexPatient raceWhite raceImmunotherapyOutcomes persistSexPatientsFactors Associated With Receipt of Molecular Testing and its Impact on Time to Initial Systemic Therapy in Metastatic Non-Small Cell Lung Cancer
Osazuwa-Peters O, Wilson L, Check D, Roberts M, Srinivasan S, Clark A, Crawford J, Chrischilles E, Carnahan R, Campbell W, Cowell L, Greenlee R, Abbott A, Mosa A, Mandhadi V, Stoddard A, Dinan M. Factors Associated With Receipt of Molecular Testing and its Impact on Time to Initial Systemic Therapy in Metastatic Non-Small Cell Lung Cancer. Clinical Lung Cancer 2023, 24: 305-312. PMID: 37055337, DOI: 10.1016/j.cllc.2023.03.001.Peer-Reviewed Original ResearchConceptsInitial systemic treatmentSystemic treatmentMolecular testingComorbidity statusMetastatic non-small cell lung cancer patientsMetastatic non-small cell lung cancerTime-varying Cox regression modelsNon-small cell lung cancer patientsProportional hazardsNon-small cell lung cancerCell lung cancer patientsInitial systemic therapyMolecular testing ratesRetrospective cohort studyMajority of patientsCell lung cancerCox regression modelLung cancer patientsNon-Hispanic white individualsCox proportional hazardsYears of ageRace/ethnicityAdult patientsCohort studyPatient age
2013
Variations in Use of PET among Medicare Beneficiaries with Non–Small Cell Lung Cancer, 1998–2007
Dinan MA, Curtis LH, Carpenter WR, Biddle AK, Abernethy AP, Patz EF, Schulman KA, Weinberger M. Variations in Use of PET among Medicare Beneficiaries with Non–Small Cell Lung Cancer, 1998–2007. Radiology 2013, 267: 807-817. PMID: 23418003, DOI: 10.1148/radiol.12120174.Peer-Reviewed Original ResearchConceptsNon-small cell lung cancerPositron emission tomographyUse of PETMedicare beneficiariesCases of NSCLCPET useDiagnosis of NSCLCEnd Results-Medicare dataMultivariable logistic regression analysisDuke University Health SystemHalf of patientsCell lung cancerExamination 2 monthsMultivariable regression analysisUniversity Health SystemLogistic regression analysisDemographic subgroupsRegression analysisInstitutional review boardNonblack patientsPrimary outcomeFinal cohortSurveillance EpidemiologyLung cancerRetrospective analysis